Sphera Funds Management Ltd. Corvus Pharmaceuticals, Inc. Transaction History

Sphera Funds Management Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$3.75 - $4.97 $891,836 - $1.18 Million	-237,823 Reduced 73.99%	83,607 $336,000
Q3 2018 Nov 14, 2018	SELL	$8.58 - $11.4 $124,899 - $165,949	-14,557 Reduced 4.33%	321,430 $2.76 Million
Q2 2018 Aug 13, 2018	BUY	$9.42 - $13.73 $137,126 - $199,867	14,557 Added 4.53%	335,987 $3.69 Million
Q1 2018 May 10, 2018	BUY	$7.48 - $11.53 $748,000 - $1.15 Million	100,000 Added 45.16%	321,430 $3.71 Million
Q3 2017 Nov 09, 2017	BUY	$11.3 - $17.23 $2.5 Million - $3.82 Million	221,430	221,430 $3.53 Million

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $413M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.